OSTX
OS Therapies Inc
$1.50
-0.05 (-3.23%)
At close · Jul 16
Going-concern doubt
— flagged May 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the unaudited consolidated financial statements are issued.”View the 10-Q filed May 18, 2026
Market Cap
$66.81M
Shares
44,538,106
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.50
Open$1.55
Day$1.46–1.56
52W$1.15–2.57
Avg vol 30d768K
Short int2.3M · 5.1% float · 2.5d
Short vol81%
DataAug 2024–Jul 2026
Filing10-Q · May 18
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 18, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
−15%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
25%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
+2%
trailing
YTD return
+7%
this year
Relative strength
−7%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
3 of 29 funds reported for Jun 30 · net -29.4K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.06% of float · ▲ +10.8% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
29 holders — near 1-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−54%
past year
ATR
10.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
25%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Distributing
3 of 29 funds reported for Jun 30 · net -29.4K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.06% of float · ▲ +10.8% MoM · 2.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
29 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $2 · 25%
52-wk high $3
vs 200-day avg -9%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OSTX
this stock
OS Therapies Inc
|
$66.81M | +7.1% | — | — | 5.1% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +4.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +7.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -11.9% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OSTX | -12.8% | -15.3% | +2.0% | -21.1% | +7.1% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -12.7% | -15.3% | -6.9% | -21.6% | -3.0% |